retatrutide diabetes type 1 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Benefits: 24% Weight Loss

Quality of life, blood safety markers, and muscle biopsies for protein biomarker analysis were also conducted at baseline and the end of the study

For the new study, researchers tracked insurance claims from nearly 127,000 overweight or obese adults who started GLP-1 treatment between 2019 and 2024, looking for people taking drugs like semaglutide (Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro), or liraglutide (Saxenda/Victoza)

Research suggests that Mounjaro may be more effective than Ozempic for blood sugar control and weight loss

Permission to use cookies By accessing this website with your browser, this means that you accept cookies and that you agree to their use